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During the development and scale-up of a FIH fed-batch cell culture process, we have encountered two major 
challenges that impacted culture performance and harvest process yield significantly.  The first challenge relates 
to the oxygen requirement for this particular process, where a higher oxygen demand was observed compared 
to our platform processes. The high oxygen demand is met by increasing agitation and sparging of air and 
oxygen in bioreactors, but also negatively impacted cell health due to higher gas entrance velocities (GEV) from 
the higher sparging rate.  The observation is exemplified in the manufacturing scale which significantly impacted 
cell culture performance and antibody production. Further exacerbating this issue, many sparger holes were 
later found to be plugged leading to a theoretical GEV as high as 300 m/s. Extensive troubleshooting studies 
were carried out at small scale to confirm the impact of high GEV on this antibody production process and led to 
the re-design of the sparger for the manufacturing scale.  Once implemented, the new sparger successfully 
mitigated the issue. The second challenge was relating to harvest operation, where the final membrane filter 
was clogged at the manufacturing scale.  Studies were performed at the pilot scale to evaluate different 
solutions including increasing depth filter area, testing different types of the final filter, and changing the chase 
buffer at the manufacturing scale. In the end, successful implementation of the new sparger design and 
optimized harvest conditions led to comparable process performance between the manufacturing scale and the 
pilot scale. The final process resulted not only in an increase in the overall product yield, but also prevented the 
need of filter change-outs during the harvest operation, therefore, significantly improving manufacturing ease.   
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